An economic case for providing free access to antiretroviral therapy for HIV-positive people in South Australia

Sexual Health

Volumn 9, Issue 3, 2012, Pages 220-226

  Heymer, Kelly Jean ^a   Wentzlaff Eggebert, Matthias ^b   Mortimer, Elissa ^b   Wilson, David P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Department of Health ^*  (Australia)

Author keywords

cost effectiveness; epidemiology; mathematical model; subsidy.

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMIC ASPECT; FEMALE; HEALTH CARE ACCESS; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; VIRUS TRANSMISSION;

AMBULATORY CARE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST SAVINGS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; MODELS, STATISTICAL; NATIONAL HEALTH PROGRAMS; SOUTH AUSTRALIA;

EID: 84862529538     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH10148     Document Type: Article

References (48)

1. National Centre in HIV Epidemiology and Clinical Research (NCHECR). HIV, viral hepatitis and sexually transmissible infections in Australia. Annual surveillance report. Sydney: NCHECR, University of New South Wales; 2010.
2. Wilson DP, Hoare A, Regan D, Wand H, Law M, et al. Mathematical models to investigate recent trends in HIV notifications among men who have sex with men in Australia. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales; 2008.
3. South Australian Department of Health. Action plan HIV 2009-2012. Adelaide: South Australian Department of Health; 2009.
4. Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment increases on dispensings of governmentsubsidised medicines in Australia. Pharmacoepidemiol Drug Saf 2008; 17: 1091-9. doi:10.1002/pds.1670
5. Grierson J, Thorpe R, Pitts M. HIV Futures 5: life as we know it. Monograph series number 60. Melbourne: The Australian Research Centre in Sex, Health and Society, Latrobe University; 2006.
6. Thaker HK, Snow MH. HIV viral suppression in the era of antiretroviral therapy. Postgrad Med J 2003; 79: 36-42. doi:10.1136/pmj.79.927.36
7. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23: 1397-404. doi:10.1097/QAD.0b013e32832b7dca
8. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372: 314-20. doi:10.1016/S0140-6736(08) 61115-0
9. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342: 921-9. doi:10.1056/NEJM2000033034 21303
10. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373: 48-57. doi:10.1016/S0140-6736(08) 61697-9
11. Shiroiwa T, Sung Y-K, Fukuda T, Lang H-C, Bae S-C, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010; 19: 422-37. doi:10.1002/hec.1481
12. Hornberger J, Holodniy M, Robertus K, Winnike M, Gibson E, Verhulst E. A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Med Decis Making 2007; 27: 789-821. doi:10.1177/0272989X07306112
13. Medicare Australia. MBS online; 2008. Available online at: http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/ Medicare-Benefits-Schedule-MBS-1 [verified October 2008].
14. Department of Health and Ageing (DHA). Pharmaceutical benefits schedule. Canberra: DHA; 2008. Available online at: http://www.pbs. gov.au/html/healthpro/ home [verified January 2009].
15. Department of Health and Human Ssevices Panel on Antiretroviral Guidelines for Adults and Adolescents. Australian commentary on DHHS guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS; 2008. Available online at: http://ashm. org.au/images/ARV/Guidelines/ AdultGL/FINAL%20amended/ V1.2APR2011.pdf [verified July 2011].
16. Health Outcomes International Pty Ltd and National Centre in HIV Epidemiology and Clinical Research. The impact of HIV/AIDS in NSW mortality, morbidity and economic impact. Sydney: New South Wales Health; 2007.
17. Prestage G, Mao L, Kippax S, Jin F, Hurley M, Grulich A, et al. Use of viral load to negotiate condom use among gay men in Sydney, Australia. AIDS Behav 2009; 13: 645-51. doi:10.1007/s10461-009-9527-0
18. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092-8. doi:10.1016/S0140- 6736(10)60705-2
19. Wilson DP. Evidence is still required for treatment as prevention for riskier routes of HIV transmission. AIDS 2010; 24: 2891-2. doi:10.1097/QAD. 0b013e328340871d
20. Fang C-T, Chang Y-Y, Hsu H-M, Twu S-J, Chen K-T, Chen M-Y, et al. Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan. J Formos Med Assoc 2007; 106: 631-40. doi:10.1016/S0929-6646(08)60020-0
21. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-31. doi:10.1056/NEJM200103153441108
22. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole S, Schwartz A, et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 2006; 20: 2207-15. doi:10.1097/QAD. 0b013e328010c7d0
23. Daly LE, Bourke GJ. Interpretation and Uses of Medical Statistics, Fifth Edition. Oxford: Blackwell Science Ltd; 2008. doi: 10.1002/9780470696750
24. Jin F, Jansson J, Law M, Prestage GP, Zablotska I, Imrie JCG, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS 2010; 24: 907-13. doi:10.1097/QAD.0b013e3283372d90
25. De Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994; 331: 341-6. doi:10.1056/ NEJM199408113310601
26. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 1997; 146: 350-7.
27. Vittinghoff E, Douglas J, Judon F, McKiman D, MacQueen K, Buchinder SP, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150: 306-11.
28. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 1149-53. doi:10.1016/S0140-6736 (00)04331-2
29. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191: 1403-9. doi:10.1086/429411
30. Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K, et al. Risk factors for HIV infection among men who have sex with men. AIDS 2006; 20: 731-9. doi:10.1097/01.aids.0000216374. 61442.55
31. Read TRH, Hocking J, Sinnott V, Hellard M. Risk factors for incident HIV infection in men having sex with men: a case-control study. Sex Health 2007; 4: 35-9. doi:10.1071/SH06043
32. Boily MC, Buve A, Baggaley RF. HIV transmission in serodiscordant heterosexual couples. BMJ 2010; 340: 1149-50.
33. Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and metaanalysis. Lancet Infect Dis 2008; 8: 553-63. doi:10.1016/S1473-3099(08)70156-7
34. Templeton DJ, Mao L, Prestage G, Kaldor JM, Kippax S, Grulich AE. Demographic predictors of circumcision status in a community-based sample of homosexual men in Sydney, Australia. Sex Health 2006; 3: 191-3. doi:10.1071/SH06009
35. Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31: 272-9. doi:10.2307/2991537
36. Weller SC, Davis KR. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; 1CD003255.
37. Pinkerton SD, Abtramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44: 1303-12. doi:10.1016/S0277-9536(96)00258-4
38. Weller SC. A meta-analysis of condom effectiveness in reducing sexually transmitted HIV. Soc Sci Med 1993; 36: 1635-44. doi:10.1016/0277-9536(93)90352-5
39. Fitch TJ, Stine C, Hager WD, Mann J, Adam MB, Mcilhaney J. Condom effectiveness: factors that influence risk reduction. Sex Transm Dis 2002; 29: 811-7. doi:10.1097/00007435-200212000-00013
40. Frankland A, Zablotska I, Prestage G, Spence G. Gay community periodic survey, Adelaide 2007. Sydney: National Centre in HIV Social Research, The University of New South Wales; 2008. Available online at: http://nchsr.arts. unsw.edu.au/pdf%20reports/ADL/GCPS/2007.pdf [verified July 2011].
41. Prestage G, Ferris J, Grierson J, Thorpe R, Zablotska I, Imrie J, et al. Homosexual men in Australia: population, distribution and HIV prevalence. Sex Health 2008; 5: 97-102. doi:10.1071/SH07080
42. Australian Bureau of Statistics (ABS). South Australia, age (full classification list) by sex. Canberra: ABS; 2006.
43. Baggaley RF, Boily M-C, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006; 20: 805-12
44. Hudgens MG, Longini IM Jr. Vanichseni S, Hu DJ, Kitayaporn D, Mock PA, et al. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am J Epidemiol 2002; 155: 159-68. doi:10.1093/aje/155.2.159
45. Wilson DP, Kwon A, Anderson J, Thein R, Law M, Maher L, et al. Return on investment 2: evaluating the cost-effectivess of needle and syringe programs in Australia. Sydney: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales; 2009.
46. Iversen J, Topp L, Maher L. Australian NSP survey national data report 2002-2006. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales; 2007.
47. Crawford JM, Kippax SC, Mao L, Van de Ven PG, Prestage GP, Grulich AE, et al. Number of risk acts by relationship status and partner serostatus: findings from the HIM cohort of homosexually active men in Sydney, Australia. AIDS Behav 2006; 10: 325-31. doi:10.1007/s10461-005-9057-3
48. Fogarty A, Mao L, Zablotska I, Salter M, Santana H, Prestage G, et al. The Health in Men and Positive Health cohorts: a comparison of trends in the health and sexual behaviour of HIV-negative and HIVpositive gay men, 2002-2005. Sydney: National Centre in HIV Social Research Annual Report of Trends in Behaviour, University of New South Wales; 2006.